Re­cent­ly stung by AAV, Sarep­ta dives a lit­tle deep­er in­to non-vi­ral de­liv­ery with newest li­cens­ing pact

The use of ade­no-as­so­ci­at­ed virus­es (AAV) as de­liv­ery ve­hi­cles for gene ther­a­peu­tics has been rid­dled with safe­ty con­cerns for years — a fact Sarep­ta knows well. Now, the phar­ma has inked a deal with a non-vi­ral de­liv­ery play­er it hopes can side­step those con­cerns al­to­geth­er.

Sarep­ta will pay out $57 mil­lion in near-term cash, as well as re­search pay­ments and “sig­nif­i­cant” down­stream mile­stones for ac­cess to GenEd­it’s poly­mer nanopar­ti­cles, a non-vi­ral de­liv­ery mech­a­nism for the com­pa­ny’s gene edit­ing ther­a­pies, the part­ners said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER